Summary
Eli Lilly and Company (LLY) reported its first-quarter 2015 financial results, showing a slight 1% decrease in worldwide revenue to $4.64 billion. This decline was primarily attributed to unfavorable foreign exchange rates and the ongoing impact of patent expirations for key drugs like Cymbalta and Evista. However, these headwinds were largely offset by the inclusion of revenue from the recently acquired Novartis Animal Health business, higher U.S. pricing, and increased volumes for several other products. Net income saw a more significant decrease of 27% to $529.5 million, translating to $0.50 earnings per share (EPS), down from $0.68 in the prior year. This drop in profitability was influenced by substantial acquired in-process research and development (IPR&D) charges and increased asset impairment, restructuring, and other special charges, particularly related to the integration of Novartis Animal Health. Despite these challenges, the company reiterated its full-year EPS guidance and maintained its revenue expectations, signaling confidence in its ongoing operations and strategic initiatives.
Financial Highlights
53 data points| Revenue | $4.64B |
| Cost of Revenue | $1.19B |
| Gross Profit | $3.45B |
| R&D Expenses | $1.04B |
| SG&A Expenses | $1.52B |
| Operating Expenses | $2.56B |
| Interest Expense | $40.90M |
| Net Income | $529.50M |
| EPS (Basic) | $0.50 |
| EPS (Diluted) | $0.50 |
| Shares Outstanding (Basic) | 1.06B |
| Shares Outstanding (Diluted) | 1.07B |
Key Highlights
- 1Worldwide revenue decreased by 1% to $4.64 billion in Q1 2015, impacted by foreign exchange and patent expirations, but supported by the Novartis Animal Health acquisition.
- 2Net income declined by 27% to $529.5 million ($0.50 EPS), largely due to significant IPR&D charges ($256 million) and restructuring costs ($108 million) related to the Novartis AH acquisition.
- 3The company completed the acquisition of Novartis Animal Health for $5.29 billion, a strategic move expected to bolster its animal health segment.
- 4Major product revenues showed mixed performance, with significant declines for Cymbalta (-40%) and Zyprexa (-22%) due to patent expirations, while Humalog and Cialis showed modest growth.
- 5Research and development expenses decreased by 6% to $1.04 billion, attributed to lower late-stage clinical development costs, partially offset by the inclusion of Novartis AH.
- 6Marketing, selling, and administrative expenses increased by 3% to $1.52 billion, driven by costs associated with the Novartis AH integration and new product launches like Trulicity and Jardiance.
- 7The company reaffirmed its full-year 2015 EPS guidance of $2.21 to $2.31, with total revenue expected between $19.5 billion and $20.0 billion.